文献速递中医内科中药与中成药合理使用

归附地黄丸经NrCAM/EGFR/PI3K/Akt通路改善脑胰岛素抵抗治疗AD

A new approach for treating AD: Guifu Dihuang Pills improves brain insulin resistance by promoting NrCAM to activate the EGFR/PI3K/Akt signaling pathway.
PubMed 文献 · J Ethnopharmacol · 2025-10-23

本研究结合RNA-seq转录组学、表面等离子共振(SPR)分析与生物信息学,系统探究归附地黄丸(GFDHP)缓解阿尔茨海默病(AD)的神经保护机制。体内采用ICV-STZ注射建立伴脑胰岛素抵抗(IR)的AD模型,体外用DXM诱导HT22细胞IR模型,并通过慢病毒shRNA敲低NrCAM验证通路。结果提示GFDHP通过上调NrCAM表达、激活EGFR/PI3K/Akt信号通路减轻IR,从而改善AD样病理与认知损害。

要点

  • 归附地黄丸可减轻ICV-STZ诱导的脑胰岛素抵抗与AD相关神经病理改变。
  • NrCAM与EGFR特异性结合并激活下游PI3K/Akt级联介导神经保护。
  • 敲低NrCAM加重IR与AD病理并削弱归附地黄丸疗效。

核心结论

  • 归附地黄丸通过上调NrCAM表达并激活EGFR/PI3K/Akt信号通路减轻脑胰岛素抵抗,从而改善AD。
  • 首次报道NrCAM作为介导该方神经保护作用的关键分子靶点,为AD治疗提供新策略。

研究设计与样本

  • 研究采用UPLC-Q-TOF/MS表征归附地黄丸化学成分
  • 体内以ICV-STZ注射建立伴脑胰岛素抵抗的AD模型
  • 体外以地塞米松处理HT22细胞诱导胰岛素抵抗模型
  • 采用慢病毒介导shRNA敲低NrCAM验证通路调控

主要发现

  • 归附地黄丸显著减轻ICV-STZ诱导的胰岛素抵抗与AD相关神经病理改变。
  • SPR分析显示NrCAM通过特异性结合EGFR介导神经保护并激活下游PI3K/Akt级联。
  • NrCAM沉默加重IR与AD病理、抑制EGFR/PI3K/Akt通路并降低归附地黄丸疗效。

临床怎么用

  • 为归附地黄丸治疗AD提供以NrCAM/EGFR/PI3K/Akt为轴的机制解释,支持其用于伴脑胰岛素抵抗的AD患者。
  • NrCAM可作为评估归附地黄丸神经保护效应的潜在分子靶点。

局限性

  • 机制验证主要基于ICV-STZ动物模型与DXM诱导的HT22细胞模型,尚需进一步临床转化验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Guifu Dihuang Pills (GFDHP), a classical Chinese herbal formula originally recorded in the Synopsis of the Golden Chamber (Jingui Yaolüe), significantly ameliorate cognitive dysfunction in patients with Alzheimer's disease (AD). However, the precise molecular mechanisms underlying its therapeutic effects, particularly those involving the regulation of cerebral insulin resistance (IR), are not yet fully elucidated. AIM OF THE STUDY: This study systematically investigated the neuroprotective mechanism of the traditional Chinese medicine (TCM) compound GFDHP in alleviating AD by integrating RNA-seq transcriptomics, surface plasmon resonance (SPR) analysis, and bioinformatic analysis. The aim was to clarify its key targets and signaling pathways involved in the modulation of cerebral IR by in vitro and in vivo experiments. METHODS: The chemical components of GFDHP were characterized using ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS). An AD model with cerebral IR was established by an intracerebroventricular streptozotocin (ICV-STZ) injection. Cognitive function was assessed using the Morris water maze (MWM) test, while hippocampal damage was evaluated by histological staining. The insulin level in hippocampal tissues was quantified using enzyme-linked immunosorbent assay (ELISA). AD-related proteins were analyzed using immunohistochemistry and Western blot. Integrated transcriptome sequencing, AlphaFold3 prediction, and SPR analysis confirmed the interaction between neuronal cell adhesion molecule (NrCAM) and epidermal growth factor receptor (EGFR). In vitro experiments were performed using HT22 cells treated with dexamethasone (DXM) to induce an IR model, followed by evaluation of IR and AD-related markers. Lentivirus-mediated shRNA knockdown of NrCAM was performed to systematically examine its regulatory effect on the EGFR/PI3K/Akt signaling pathway and GFDHP's therapeutic intervention. RESULTS: GFDHP significantly attenuated ICV-STZ-induced IR and AD-related neuropathological alterations. SPR analysis further revealed that NrCAM mediated the neuroprotective effect through the specific binding to EGFR, thereby activating the downstream PI3K/Akt signaling cascade. NrCAM silencing not only exacerbated both IR and AD pathology but also suppressed the EGFR/PI3K/Akt pathway and reduced the therapeutic effect of GFDHP. CONCLUSIONS: This study demonstrated that GFDHP alleviated IR by upregulating NrCAM expression and subsequently activating the EGFR/PI3K/Akt signaling pathway, thereby ameliorating AD. This is the first report identifying NrCAM as the key molecular target mediating the neuroprotective effect of this herbal formulation, providing a novel therapeutic strategy for AD treatment.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Yu C, Liu L, Lu Z, et al. A new approach for treating AD: Guifu Dihuang Pills improves brain insulin resistance by promoting NrCAM to activate the EGFR/PI3K/Akt signaling pathway. J Ethnopharmacol. 2025. PMID: 41139043. doi:10.1016/j.jep.2025.120642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。